Study of 225Ac-SS0110 in Subjects With ES-SCLC or MCC (SANTANA-225 )

Stopped early · Phase 1/Phase 2

Conditions studied: Small Cell Lung Cancer Extensive Stage, Merkel Cell Carcinoma

In brief

This study aims to determine safety, tolerability, recommended phase 2 dose (RP2D), and preliminary antitumor activity of 225Ac-SSO110 with standard of care (SoC) therapy in patients with somatostatin receptor 2 expressing (SSTR2+) extensive-stage small cell lung cancer (ES-SCLC) and recurrent locally advanced or metastatic Merkel cell carcinoma (MCC).

Key facts

Study ID

NCT06939036

Run by

Ariceum Therapeutics GmbH

People needed

2

Starts

2025-07-01

Expected to finish

2025-12-31

Last updated by the study team

2026-02-05

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Biogenix Molecular — Miami, Florida, United States
• University of Louisville Health-Brown Cancer Center — Louisville, Kentucky, United States
• United Theranostics — Glen Burnie, Maryland, United States
• John Theurer Cancer Center at Hackensack UMC — Hackensack, New Jersey, United States
• UPMC — Pittsburgh, Pennsylvania, United States
• Virginia Cancer Specialists, PC — Fairfax, Virginia, United States
• GenesisCare — Alexandria, Australia

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.